Purpose: To develop a new ectasia risk model through artificial intelligence (AI) and machine learning, enabling the creation of an integrated method without a cut-off point per risk factor, and subsequently better at differentiating patients at higher risk of ectasia with normal topography.

Methods: This comparative case-control study included 339 eyes with normal preoperative topography, with 65 eyes that developed ectasia after laser in situ keratomileusis (ectasia group) and 274 eyes that did not develop ectasia (control group). The AI model used known risk factors to engineer 14 additional ones, totaling 20 features. In this methodology, no variable is used in isolation because its cut-off point is never considered. All separation between cases and controls is made through the interaction detected by the machine learning model that gathers the variables considered relevant. The ability to correctly separate ectatic cases identified as high risk, ectatic cases wrongly classified as low risk, and controls were illustrated by the diagram t-distributed stochastic neighbor embedding (t-SNE).

Results: Only two original variables (percent tissue altered and corneal thickness) and two derived from the feature engineering process (derivative percent tissue altered and age weighted value) were selected by the final AI model (ie, best performing AI-based model to separate patients at higher risk). The t-SNE visualization demonstrated the greater ability to differentiate between patients considered at risk by the AI-based model, without a cut-off point, compared to all other methods used alone ( < .0001).

Conclusions: This study describes a new AI-based model that integrates different risk factors without a cut-off point, increasing the number of cases correctly identified as at higher risk. .

Download full-text PDF

Source
http://dx.doi.org/10.3928/1081597X-20221018-01DOI Listing

Publication Analysis

Top Keywords

cut-off point
20
higher risk
12
ai-based model
12
risk
10
ectasia risk
8
model
8
risk model
8
method cut-off
8
artificial intelligence
8
develop ectasia
8

Similar Publications

Whilst severe liver dysfunction is rarely encountered at the time of diagnosis for patients with acute myeloid leukemia (AML), mild elevations aminotransferase (<5 times the upper limit of normal) may be more frequently seen. Liver dysfunction at the time of diagnosis of AML is a parameter that requires investigation and can assist the clinicians in predicting prognosis. The aim of the present study was to investigate liver dysfunction at the time of diagnosis using the assoicated parameters in patients with AML.

View Article and Find Full Text PDF

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.

J Prev Alzheimers Dis

January 2025

Clinical Memory Research Unit, Clinical Sciences in Malmö, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Sweden. Electronic address:

As novel, anti-amyloid therapies have become more widely available, access to timely and accurate diagnosis has become integral to ensuring optimal treatment of patients with early-stage Alzheimer's disease (AD). Plasma biomarkers are a promising tool for identifying AD pathology; however, several technical and clinical factors need to be considered prior to their implementation in routine clinical use. Given the rapid pace of advancements in the field and the wide array of available biomarkers and tests, this review aims to summarize these considerations, evaluate available platforms, and discuss the steps needed to bring plasma biomarker testing to the clinic.

View Article and Find Full Text PDF

Real-world tafamidis experience in hereditary transthyretin amyloidosis with peripheral neuropathy in Brazil.

Arq Neuropsiquiatr

January 2025

Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello, Rio de Janeiro RJ, Brazil.

Background:  Tafamidis is a kinetic stabilizer that binds to the transthyretin (TTR) gene, inhibiting its dissociation. It is the only disease-modifying treatment for hereditary TTR amyloidosis with peripheral neuropathy (ATTRv-PN) available in the National Therapeutic Form (Formulário Terapêutico Nacional, FTN, in Portuguese) of the Brazilian Unified Health System (Sistema Único de Saúde, SUS, in Portuguese).

Objective:  To assess if the efficacy and safety of tafamidis in the Brazilian real-world experience are comparable to the results of clinical trials.

View Article and Find Full Text PDF

Novel pain assessment tool specific for pulp symptoms to aid diagnosis.

Int Endod J

January 2025

Division of Conservative Dentistry and Endodontics, Centre for Dental Education and Research, All India Institute of Medical Sciences, New Delhi, India.

Aim: Although many pain assessment tools exist, none are specific to the relatively unique presentation of pulpal pain. The aim of this study was to develop and validate a novel pain assessment tool based on pulp symptoms.

Methodology: A preliminary list of items best-describing pulpitis was developed based on deductive and inductive approaches and the preliminary tool was piloted (n = 80).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!